vida: extract claims from 2026-04-08-glp1-semaglutide-tirzepatide-cardiac-mechanism

- Source: inbox/queue/2026-04-08-glp1-semaglutide-tirzepatide-cardiac-mechanism.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Broad appetite suppression reduces micronutrient intake at scale creating a population-level safety signal that current deployment models do not address
+confidence: likely
+source: IAPAM cohort study (n=461,382), AHA/ACLM/ASN/OMA/TOS joint advisory in AJCN 2025
+created: 2026-04-08
+title: GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
+agent: vida
+scope: causal
+sourcer: IAPAM
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
+
+A large cohort study of 461,382 GLP-1 users found that 12.7% developed new nutritional deficiency diagnoses at 6 months of therapy, rising to 13.6% for vitamin D deficiency by 12 months. Deficiencies in iron, B vitamins, calcium, selenium, and zinc also increased over time. The mechanism is straightforward: GLP-1 receptor agonists suppress appetite broadly, reducing total caloric intake including micronutrient-rich foods. This is not a rare adverse effect but a common one affecting more than one in eight users. The clinical significance is underscored by the first formal multi-society guidance (AHA/ACLM/ASN/OMA/TOS joint advisory in American Journal of Clinical Nutrition, 2025) specifically addressing nutritional monitoring and supplementation for GLP-1 users. IAPAM clinical practice updates from October 2025 through February 2026 document practitioners reporting increasing presentations of GLP-1-related complications including muscle mass loss (sarcopenia), hair loss (telogen effluvium from protein/micronutrient depletion), and bone density concerns. The gap is operational: GLP-1 is being prescribed at unprecedented scale with a simple 'inject and lose weight' narrative, but the medical system lacks the monitoring infrastructure to systematically catch and correct these deficiencies before they produce secondary health effects that may undermine the metabolic benefits of weight loss.

domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Real-world evidence from 10,625 matched ASCVD patients shows pure GLP-1R agonism may produce direct cardiac benefits that dual GIP/GLP-1 agonism partially offsets
+confidence: speculative
+source: STEER investigators 2026, Nature Medicine 2025
+created: 2026-04-08
+title: Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
+agent: vida
+scope: causal
+sourcer: STEER investigators / Nature Medicine
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
+
+The STEER study (n=10,625 matched patients with overweight/obesity and ASCVD without diabetes) found semaglutide associated with 29% lower revised 3-point MACE versus tirzepatide (HR 0.71), 22% lower revised 5-point MACE, and in per-protocol analysis 43-57% reductions in favor of semaglutide. This finding is counterintuitive because tirzepatide produces greater weight loss than semaglutide, and the prevailing assumption has been that GLP-1 cardiovascular benefits operate primarily through weight reduction. A separate Nature Medicine 2025 study in T2D patients found semaglutide associated with lower risk of hospitalization for heart failure or all-cause mortality versus tirzepatide. The proposed mechanism is that GLP-1 receptors are expressed directly in cardiac tissue, and pure GLP-1 receptor agonism (semaglutide) may produce direct cardioprotective effects via cAMP signaling, cardiac remodeling inhibition, or anti-inflammatory pathways that are independent of weight loss. Tirzepatide's dual GIP/GLP-1 receptor activity may partially offset GLP-1R-specific cardiac benefits through GIP receptor signaling in cardiac tissue. However, this is real-world evidence from observational data, not an RCT, creating potential for confounding by prescribing patterns (who gets prescribed which drug may differ systematically). The mechanism is proposed but not definitively established through basic science. Funding sources are unclear, and Novo Nordisk (semaglutide manufacturer) would benefit from this finding. Confidence is speculative pending replication and mechanistic confirmation.

inbox/archive/health/2026-04-08-glp1-semaglutide-tirzepatide-cardiac-mechanism.md

@@ -7,9 +7,12 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: journal-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-08
 priority: medium
 tags: [GLP-1, semaglutide, tirzepatide, cardiovascular, mechanism, GLP-1R, GIP-receptor, heart-failure, MACE]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-04-08-hfsa-2024-heart-failure-rising.md

@@ -7,9 +7,12 @@ date: 2024-09-01
 domain: health
 secondary_domains: []
 format: journal-article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-08
 priority: high
 tags: [heart-failure, HFpEF, mortality, epidemiology, disparities, racial-health-equity, cardiovascular]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content